Aptamer Group plc has reported significant progress across its strategic initiatives, including the delivery of its first AI-generated Optimer® candidates for laboratory testing, demonstrating the rapid development of its AI platform which has been trained on 450,000 sequences. The company has also invested in automation equipment to enhance discovery capabilities and is advancing its therapeutic pipeline, with radioligand therapy programmes nearing first in vivo data by the end of 2026, achieving over 99% radiochemical purity in radiolabelling. Furthermore, Aptamer has identified promising kidney-targeting siRNA delivery vehicles with excellent selectivity, adding to its versatile delivery vehicle portfolio.
